Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MedImmune FluMist "complete response"

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

MedImmune plans to respond to its second "complete response" letter for FluMist before the end of August. The July 10 letter raises 24 manufacturing questions and 44 clinical questions relating to the influenza vaccine, including the issue of exacerbated rates of asthma and wheezing in patients 18 to 35 months of age. MedImmune is considering excluding the subpopulation from the indication as one way to address the problem, the company told a July 11 conference call. Increased reactogenicity in asthmatics was raised as an issue during a July 2001 advisory committee review. MedImmune does not expect to launch FluMist in time for the 2002 flu seaso

You may also be interested in...

EU MDR Notified Body Designations Could Soar By A Third By End Of 2021

There could be 28 notified body designations in total under the Medical Device Regulation by the end of 2021. But there is cause for concern over designations under the IVD Regulation, which are lagging far behind.

Swiss Health Providers Turn Heat On Federal Council: 12% Loss Of Medtech Products Likely On EU MRA Failure

A consortium of Swiss providers, patient groups and health care trade bodies is imploring the federal council to avert a looming patient care crisis in Switzerland if the EU MRA cannot be agreed.

New China COVID Vaccine Arriving But COVAX Pledge May Need A Booster

China’s first domestically-developed recombinant protein vaccine for COVID-19 moves forward in late-stage trials in two countries.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts